Harsh K. Agarwal1,
2, Kinzya Grant2, Baris I. Turkbey2, Yuxi Pang3,
Marcelino Bernardo2, 4, Julien Sngas5,
Dagane Daar2, 4, Junaita Weaver2, 4,
Jochen Keupp5, Maria J. Merino6, Bradford Wood7,
Peter A. Pinto8, Peter L. Choyke2
1Philips
Research North America, Briarcliff Manor, NY, United States; 2Molecular
Imaging Program, NCI, National Institute of Health, Bethesda, MD, United
States; 3Philips Healthcare, Cleaveland, OH, United States; 4SAIC
Frederick Inc., Frederick, MD, United States; 5Philips Research
Laboratories, Hamburg, Germany; 65Laboratory of Pathology, NCI,
National Institute of Health, Bethesda, MD, United States; 7NIH
Center for Interventional Oncology, National Institute of Health, Bethesda,
MD, United States; 8Urologic Oncology Branch, National Institute
of Health, Bethesda, MD, United States
ADC maps estimated from single compartment analysis of DW-MRI have been successfully used in prostate oncology to identify and stage the tumor aggressiveness with its Gleason score. However, at higher b-values the multi-compartment diffusion nature of the tumor tissue becomes apparent providing good contrast between the tumor and the normal prostate tissue due to the complete suppression of the normal tissue. Simple ADC measures such as ADC from b=0 and 2000 and ADC from 0 and 1000 b value DW-MRI images were compared with ADC from regular DW-MRI images b=0,188,350,563 and 750 to show similar tumor grading performance with better background suppression with high b value DW-MRI.